World stem cell leaders will converge on Promega’s BioPharmaceutical
Technology Center in Fitchburg, Wisconsin, on April 30 for the 9th
Annual Wisconsin Stem Cell Symposium: From Stem Cells to Blood.
Coordinated by the nonprofit BioPharmaceutical Technology Center Institute, the University of Wisconsin-Madison Stem Cell and Regenerative Medicine Center
and the UW-Madison Blood Research Program, this year’s symposium is
focused on how the stem cells that give rise to blood develop and
It will also look at the diversity of insights stem cell
studies have provided other fields.
Highlighted topics include genesis and regulation of progenitor cells
and hematopoietic stem cells, stem cell genomes/epigenomes, stem cell
microenvironment, and tumor initiating
‘Yet again the Lazio region risks missing a chance to be at the cutting edge in the country for the therapeutic use of hematopoietic stem cells, a technique that is scientifically tested and proven in terms of its efficiency,’ said Luigi Canai, the President of the Lazio Health Commission, in a statement.
‘For days the media has been reporting important progress achieved in this field of research both abroad and in Italy. Regarding this subject, a year ago on February 19 2009, the commission chaired by me approved a unified text for a law that was later approved by
Italy is the top country in the world for hematopoietic stem cell transplants per million inhabitants, said Alessandro Nanni Costa, the director of the National Transplant Center (CNT), presenting data today in Rome from a study by the Welfare Minister on umbilical cord stem cells.
Italy boasts a registry of 370,000 healthy adults available to donate blood stem cells.
The units of umbilical cord blood preserved in Italian biobanks number 17,503, while in 2008, only 141 were used in Italy or abroad.
The objective is to reach 80,000-90,000 units of umbilical cords preserved from which blood stem cells can be removed
Gerhard Bauer, an American researcher and expert on ‘mother’ stem cells, during the 50th congress of the American Society of Hematology (ASH) in San Francisco, announced that human testing for an AIDS treatment based on genetically modified stem cells could begin within 5 years. Bauer has been working for the past 10 years on modified stem cells that could repair strongly compromised immune systems in HIV patients. “For this reason the apparent success obtained by German researchers on an American patient with AIDS and leukemia reinforces the idea that we are on the right path.”
Last month the German
Gerhard Bauer & Jan A. Nolta
A new experimental technique in the future will remove skin cells from HIV patients, manipulate the cells bringing them to a state similar to that of stem cells, and then re-implant them in the same patient to eliminate the virus. The technique is still in the experimental phase in mice, but according to Gerhard Bauer, presenting the initial results of his study today at the 50th American Society of Hematology Congress in San Francisco, it’s a possibility. Bauer has been working for more than 10 years on this technique together with